Free Topics
About
Acute Coronary Syndromes, Unstable Angina
Adverse Drug Reactions
Alpha (1)-Antitrypsin Deficiency
Calculator - Fractional Excretion of Sodium
Calculator - Fractional Excretion of Urea
Figure - Acetaminophen (Rumack-Matthew) Nomogram
Figure - Activation of the Sympathetic Nervous System
Flowchart - Advanced Cardiac Life Support Pulseless Arrest Algorithm
Flowchart - Bradycardia Algorithm
Heparin-Induced Thrombocytopenia
Inflammatory Bowel Disease
Qualitative Platelet Disorders
Rheumatoid Arthritis
Table - 4T Scoring System for Pretest Probability of Heparin-Induced Thrombocytopenia
Table - AASLD Treatment Guidelines for Chronic Hepatitis B
1. Inpatient Care in Internal Medicine
2. Nutrition Support
2. Nutrition Support
Assessment of Nutritional Status
Enteral Nutrition
Nutrient Requirements
Parenteral Nutrition
References
Table(s)
2-1. Estimated Energy Requirements for Hospitalized Patients Based on Body Mass
2-2. Recommended Daily Protein Intake
2-3. Trace Minerals, Fat-Soluble Vitamins, and Water-Soluble Vitamins: Recommended Daily Intake,
2-4. Guidelines for Vitamin and Mineral Supplementation in Patients with Severe
2-5. Electrolyte Concentrations in Gastrointestinal Fluids
2-6. Enteral Feeding Formulas: Comparing Composition
2-7. Major Mineral Daily Requirements, Deficiency, Toxicity, and Diagnostic Evaluation
3. Preventive Cardiology
3. Preventive Cardiology
Dyslipidemia
Hypertension
References
Table(s)
3-1. Manifestations of Target Organ Disease
3-10. Statin Therapy Regimens by Intensity
3-2. Classification of Blood Pressure for Adults Age 18 Years and Older
3-3. Lifestyle Modifications and Effects
3-4. Commonly Used Antihypertensive Agents by Functional Class
3-5. Parenteral Antihypertensive Drug Preparations
3-6. Physical Properties of Plasma Lipoproteins
3-7. Differential Diagnosis of Major Lipid Abnormalities
3-8. Review of Major Genetic Dyslipoproteinemias
3-9. Nutrient Composition of the Therapeutic Lifestyle Change Diet
4. Ischemic Heart Disease
4. Ischemic Heart Disease
Acute Coronary Syndromes, Unstable Angina
Coronary Heart Disease and Stable Angina
Figure(s)
4-1. Approach to the Evaluation and Management of the Patient with
4-2. Fourteen-Day Rates of Death, MI, or Urgent Revascularization from the
4-3. Diagnostic and Therapeutic Approach to Patients Presenting with Acute Coronary
4-4. The Benefit of Coronary Reperfusion is Inversely Related to Ischemia
4-5. Strategies for Coronary Reperfusion and Risk Assessment
References
ST-Segment Elevation Myocardial Infarction
Table(s)
4-1. Canadian Cardiovascular Society (CCS) Classification System
4-10. Killip Classification
4-11. Appropriate Selection of Routine Invasive Versus Ischemia-Driven Revascularization Strategy in
4-12. Antiplatelet Agents in UA/NSTEMI
4-13. Anticoagulant Medications
4-14. Electrocardiogram-Based Anatomic Distribution
4-15. Criteria for ST-Segment Elevation for Prior LBBB or RV-Paced Rhythm
4-16. Differential Diagnosis of ST-Segment Elevation on ECG Excluding STEMI
4-17. Upstream Medical Therapy
4-18. Fibrinolytic Agents
4-19. Contraindications to Thrombolytic Therapy
4-2. Pretest Probability of Coronary Artery Disease by Age, Gender, and
4-3. Differential Diagnosis of Chest Pain Excluding Epicardial Atherosclerosis
4-4. Conditions That May Provoke or Exacerbate Ischemia/Angina Independent of Worsening
4-5. Diagnostic Accuracy of Common Stress Testing Modalities in Patients Without
4-6. Exercise Stress Testing: Duke Treadmill Score
4-7. Beta-Blockers Commonly Used for Ischemic Heart Disease
4-8. Calcium Channel Blockers Commonly Used for Ischemic Heart Disease
4-9. Nitrate Preparations Commonly Used for Ischemic Heart Disease
5. Heart Failure and Cardiomyopathy
6. Pericardial and Valvular Heart Disease
7. Cardiac Arrhythmias
7. Cardiac Arrhythmias
Bradyarrhythmias
Figure(s)
7-1. Diagnostic Approach to Tachyarrhythmias
7-2. A and B, Brugada Criteria for Distinguishing Ventricular Tachycardia from
7-3. Approach to Bradyarrhythmias
7-4. Examples of Sinus Node Dysfunction
7-5. Examples of Atrioventricular Block (AVB)
7-6. Pacemaker Rhythms
7-7. Algorithm for the Evaluation of Syncope
Table(s)
7-1. Treatment of Common Supraventricular Tachyarrhythmias
7-2. Common Vagal Maneuvers and Adenosine
7-3. Pharmacologic Agents Used for Heart Rate Control in Atrial Fibrillation
7-4. Annual Stroke Risk in Patients with Nonvalvular Atrial Fibrillation Not
7-5. Commonly Used Antiarrhythmic Drugs
7-6. Causes of Bradycardia
Tachyarrhythmias
8. Critical Care
9. Obstructive Lung Disease
9. Obstructive Lung Disease
Asthma
Chronic Obstructive Pulmonary Disease
Figure(s)
References
Table(s)
9-1. Pharmacotherapy for Smoking Cessation
9-10. Classification of Asthma Severity on Initial Assessment
9-11. Assessment of Asthma Control
9-12. Classification of Asthma Exacerbation Severity
9-13. Conditions That Can Present As Refractory Asthma
9-14. Comparative Daily Adult Dosages for Inhaled Corticosteroids
9-15. Fda-Approved Biologics for Asthma
9-2. Chronic Obstructive Pulmonary Disease Assessment Tool (CAT)
9-3. Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index
9-4. Classification of Severity of Airflow Limitation in Chronic Obstructive Pulmonary
9-5. Refined Abcd Assessment Tool for Chronic Obstructive Lung Disease
9-6. Inhaler Pharmacotherapy for Chronic Asthma and Chronic Obstructive Pulmonary Disease
9-7. Pharmacotherapy for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
9-8. Indications and Contraindications for Noninvasive Ventilation in Acute Exacerbations of
9-9. Indications for Invasive Mechanical Ventilation in Acute Exacerbations of Chronic
10. Pulmonary Diseases
10. Pulmonary Diseases
Cystic Fibrosis
Figure(s)
10-1. Algorithm for Diagnostic Workup of Pulmonary Hypertension
10-2. Algorithm for Management of Pulmonary Arterial Hypertension
10-3. Usual Interstitial Pneumonitis
10-4. Nonspecific Interstitial Pneumonitis
10-5. Algorithm for Evaluation of Hemoptysis
10-6. Diagnostic and Therapeutic Management of Low- and Intermediate-Risk Pulmonary Nodules
Hemoptysis
Interstitial Lung Disease
Obstructive Sleep Apnea-Hypopnea Syndrome
Pleural Diseases
Pulmonary Hypertension
References
Solitary Pulmonary Nodule
Table(s)
10-1. Clinical Classification of Pulmonary Hypertension: Dana Point (2008) Classification System
10-10. Epidemiology of Hemoptysis
10-11. Currently Fda-Approved Cftr Modulators
10-12. Assessment of the Probability of Malignancy
10-13. Differential Diagnosis of the Solitary Pulmonary Nodule (SPN)
10-14. Causes of Pleural Effusion
10-15. Criteria for Defining an Effusion
10-16. Helpful Features of Exudative Pleural Effusions
10-2. Vasomodulator/Vasodilatory Therapy for Pulmonary Arterial Hypertension
10-3. Validated Risk Assessment Tools in Pah
10-4. Symptoms Associated with Obstructive Sleep Apnea-Hypopnea Syndrome
10-5. Mallampati Airway Classification
10-6. Clinical and Radiologic Features of Interstitial Lung Diseases
10-7. Medical Treatment of Selected Interstitial Lung Diseases
10-8. Scadding Staging of Sarcoidosis
10-9. Etiology of Hemoptysis
11. Allergy and Immunology
12. Fluid and Electrolyte Management
13. Renal Diseases
13. Renal Diseases
Acute Kidney Injury
Deposition Disorders/Dysproteinemias
Diabetic Nephropathy
Evaluation of the Patient with Renal Disease
Figure(s)
Focal Segmental Glomerulosclerosis
Glomerulopathies
IgA Nephropathy/Henoch-Schonlein Purpura
Lupus Nephritis
Management of Chronic Kidney Disease
Membranoproliferative Glomerulonephritis
Membranous Nephropathy
Minimal Change Disease
Nephrolithiasis
Polycystic Kidney Disease
Postinfectious Glomerulonephropathy
Pulmonary-Renal Syndromes
Renal Replacement Therapies
Table(s)
14. Treatment of Infectious Diseases
14. Treatment of Infectious Diseases
Bioterrorism and Emerging Infections
Bite Wounds
Bloodstream Infections and Catheter-Related Bloodstream Infections
Cardiovascular Infections
Central Nervous System Infections
Fungal and Atypical Organisms
Gastrointestinal and Abdominal Infections
Genitourinary Infections
Health Care-Associated Infections
Lower Respiratory Tract Infections
Mosquito-Borne Infections
Principles of Therapy
Skin, Soft-Tissue, and Bone Infections
Anaerobic Myonecrosis (Gas Gangrene)
Complicated Skin and Soft-Tissue Infections
Infected Decubitus Ulcers and Limb-Threatening Diabetic Foot Ulcers
Necrotizing Fasciitis
Nonpurulent Skin and Soft-Tissue Infections (Erysipelas and Cellulitis)
Osteomyelitis
Purulent Skin and Soft-Tissue Infections (Furuncles, Carbuncles, Abscesses)
Table(s)
14-1. Treatment of Toxic Shock Syndromes
14-10. Empiric Therapy Examples for Intra-Abdominal Infections
14-11. Empiric Therapy for Urinary Tract Infections
14-12. Dosing Examples for Urinary Tract Infections
14-13. Treatment of Fungal Infections, Nocardia, and Actinomyces
14-14. Emerging Infectious Diseases
14-2. Treatment of Osteomyelitis
14-3. Typical Cerebrospinal Fluid Findings in Meningitis
14-4. Treatment of Common Pathogens Associated with Bloodstream Infections and Catheter-Related
14-5. Modified Duke Criteria for the Diagnosis of Infective Endocarditis
14-6. Definition of Infective Endocarditis (IE) by Modified Duke Criteria
14-7. Treatment of Endocarditis Caused by Specific Organisms
14-8. Endocarditis Prophylaxis
14-9. Empiric Treatment for Community-Acquired Pneumonia
Tick-Borne Infections
Toxic Shock Syndrome
Toxin-Mediated Infections
Upper Respiratory Tract Infections
Zoonoses
15. Antimicrobials
15. Antimicrobials
Antifungal Agents
Antimicrobial Agents
Aminoglycosides
Carbapenems
Cephalosporins
Colistin and Polymyxin B
Cyclic Lipopeptide
Fluoroquinolones
Lipoglycopeptides
Long-Acting Lipoglycopeptides
Macrolides and Lincosamides
Monobactams
Nitroimidazole
Oxazolidinones
Penicillins
Pleuromutilin
Streptogramin
Sulfonamides and Trimethoprim
Tetracyclines
Uncomplicated UTI Agents
Vancomycin
Antimycobacterial Agents
Antiviral Agents
Figure(s)
Introduction
Table(s)
16. Sexually Transmitted Infections, Human Immunodeficiency Virus, and Acquired Immunodeficiency Syndrome
16. Sexually Transmitted Infections, Human Immunodeficiency Virus, and Acquired Immunodeficiency Syndrome
Associated Neoplasms
Central Nervous System and Retinal Disease
Diarrhea
Esophagitis
Febrile Syndromes
Figure(s)
Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome
Pulmonary Syndromes
Sexual History and Gender-Affirming Care
Sexually Transmitted Infections in Patients with HIV
Sexually Transmitted Infections: Ulcerative Diseases
Sexually Transmitted Infections: Vaginitis and Vaginosis
Table(s)
17. Solid Organ Transplant Medicine
18. Gastrointestinal Diseases
19. Liver Diseases
20. Disorders of Hemostasis and Thrombosis
20. Disorders of Hemostasis and Thrombosis
Acquired Coagulation Disorders
Figure(s)
Hemostasis Disorders
Inherited Bleeding Disorders
Platelet Disorders
Table(s)
20-1. Factor Deficiencies That Cause Prolonged Prothrombin Time and/or Activated Partial
20-2. Classification of Thrombocytopenia
20-3. 4T Scoring System for Pretest Probability of Heparin-Induced Thrombocytopenia
20-4. International Society on Thrombosis and Haemostasis Disseminated Intravascular Coagulation Scoring
20-5. European Society of Cardiology Mortality Risk Classification of Patients Who
20-6. Anticoagulants for Treatment of Venous Thromboembolism (Vte)
Venous Thromboembolic Disorders
21. Hematologic Disorders and Transfusion Therapy
22. Cancer
22. Cancer
Gastrointestinal Malignancies
General Principles
Genitourinary Malignancies
Gynecologic Malignancies
Hematologic Malignancies
Oncologic Emergencies and Supportive Care
Solid Malignancies
Table(s)
22-1. Estimated New Cancer Cases and Rates of Death for Most
22-10. Select Chromosomal Abnormalities in B-Cell Non-Hodgkin Lymphomas
22-11. Revised-International Staging System and Risk Stratification in Myeloma
22-12. Oncologic Emergencies
22-2. List of Selected Familial Cancer Syndromes with High Penetrance
22-3. Eastern Cooperative Oncology Group (ECOG) and Karnofsky Score
22-4. Summary of Selected Response Evaluation Criteria in Solid Tumors (RECIST)
22-5. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes
22-6. Acute Leukemias with Recurrent Genetic Abnormalities
22-7. Cytogenetic Abnormalities in Acute Myeloid Leukemia and Associated Prognosis
22-8. Chronic Lymphocytic Leukemia Clinical Staging
22-9. Lugano Staging of Lymphomas
23. Diabetes Mellitus and Related Disorders
24. Endocrine
24. Endocrine
Acromegaly
Adrenal Failure
Cushing Syndrome
Evaluation of Thyroid Function
Goiter, Thyroid Nodules, and Thyroid Carcinoma
Hyperprolactinemia
Hyperthyroidism
Hypothyroidism
Incidental Adrenal Nodules
Osteomalacia
Paget Disease
Pituitary Adenomas and Hypopituitarism
References
Table(s)
Transgender Medicine
25. Arthritis and Rheumatologic Diseases
25. Arthritis and Rheumatologic Diseases
Basic Approach to Joint Pain
Crystalline Arthritis
Figure(s)
Large Vessel Vasculitis
Medications in Rheumatology
Medium Vessel Vasculitis
Rheumatoid Arthritis
Small Vessel Vasculitis
Table(s)
25-1. Synovial Fluid Analysis
25-10. Nomenclature
25-11. Biologic Dmards
25-2. Acute Gout Treatment
25-3. Urate-Lowering Therapies
25-4. Distinguishing Manifestations
25-5. Synthetic Dmards
25-6. Myositis-Specific Antibodies (Msa)
25-7. Vasculitis Classification
25-8. Vasculitis Features by Vessel Size
25-9. Sensitivity of Anca Antibodies
26. Medical Emergencies
27. Neurologic Disorders
27. Neurologic Disorders
Acute Spinal Cord Dysfunction
Alterations in Consciousness
Alzheimer Disease
Cerebrovascular Disease
Figure(s)
Head Trauma
Headache
Multiple Sclerosis
Neuromuscular Disease
Parkinson Disease
Seizures
Table(s)
27-1. Causes of Altered Mental Status
27-10. Differential Diagnosis of Parkinson Disease
27-11. Differential Diagnosis of Acute Immune Demyelinating Polyneuropathy
27-2. Ape2 Score
27-3. Differential Diagnosis of Alzheimer Dementia
27-4. Etiologies of Seizures
27-5. Disease-Modifying Therapies Approved for Use in Relapsing-Remitting Multiple Sclerosis
27-6. Inclusion and Exclusion Criteria for t-PA for Acute Ischemic Stroke
27-7. Inclusion and Exclusion Criteria for Endovascular Thrombectomy (Washington University Stroke
27-8. Secondary Stroke Prevention ('Blasted')
27-9. Causes of Acute Spinal Cord Dysfunction
28. Toxicology
Appendices
A. Immunizations and Postexposure Therapies
A. Immunizations and Postexposure Therapies
T - A-1. Selected Adult Immunization Recommendations in the United States
T - A-2. Selected Adult Postexposure Prophylaxis Recommendations
T - A-3. Selected Postexposure Guidelines for Healthcare Personnel
T - A-4. Rabies Postexposure Prophylaxis Recommendations
B. Infection Control and Isolation Recommendations
C. Advanced Cardiac Life Support Algorithms
Front Matter
